VERTEX PHARMACEUTICALS INC / MA Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent of $39.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent · last filed 2026-08-04
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax, parent for the quarter ending 2026-06-30 was $39.70M.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax, parent for the quarter ending 2026-03-31 was $84.90M.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax, parent for the quarter ending 2025-12-31 was $50.60M, a 64.54% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax, parent for the quarter ending 2025-09-30 was $33.50M.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax, parent for fiscal 2025 was -$198.10M, a 245.66% decline from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax, parent for fiscal 2024 was $136.00M.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax, parent for fiscal 2023 was -$50.90M.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax, parent for fiscal 2022 was -$4.10M, a 104.93% decline from fiscal 2021.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent 3 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent 3 month as first filed | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent 6 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent 6 month as first filed | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent 9 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent 9 month as first filed | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $39.70M 10-Q · filed 2026-08-04 | $124.60M 10-Q · filed 2026-08-04 | $175.20M derived: sum of 3 quarters · filed 2026-08-04 | $208.70M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2026-03-31 | $84.90M 10-Q · filed 2026-05-05 | $135.50M derived: sum of 2 quarters · filed 2026-05-05 | $169.00M derived: sum of 3 quarters · filed 2026-05-05 | -$22.90M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-12-31 | $50.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $84.10M derived: sum of 2 quarters · filed 2026-02-13 | -$107.80M derived: sum of 3 quarters · filed 2026-08-04 | -$198.10M 10-K · filed 2026-02-13 | |||
| 2025-09-30 | $33.50M 10-Q · filed 2025-11-04 | -$158.40M derived: sum of 2 quarters · filed 2026-08-04 | -$248.70M 10-Q · filed 2025-11-04 | -$106.00M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-06-30 | -$191.90M 10-Q · filed 2026-08-04 | -$282.20M 10-Q · filed 2026-08-04 | -$139.50M derived: sum of 3 quarters · filed 2026-08-04 | -$202.50M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-03-31 | -$90.30M 10-Q · filed 2026-05-05 | $52.40M derived: sum of 2 quarters · filed 2026-05-05 | -$10.60M derived: sum of 3 quarters · filed 2026-05-05 | $1.20M derived: sum of 4 quarters · filed 2026-05-05 | |||
| 2024-12-31 | $142.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $79.70M derived: sum of 2 quarters · filed 2026-02-13 | $91.50M derived: sum of 3 quarters · filed 2026-02-13 | $136.00M 10-K · filed 2026-02-13 | |||
| 2024-09-30 | -$63.00M 10-Q · filed 2025-11-04 | -$51.20M derived: sum of 2 quarters · filed 2025-11-04 | -$6.70M 10-Q · filed 2025-11-04 | -$63.50M derived: sum of 4 quarters · filed 2026-02-13 | |||
| 2024-06-30 | $11.80M 10-Q · filed 2025-08-05 | $56.30M 10-Q · filed 2025-08-05 | -$500.00K derived: sum of 3 quarters · filed 2026-02-13 | $47.50M derived: sum of 4 quarters · filed 2026-02-13 | |||
| 2024-03-31 | $44.50M 10-Q · filed 2025-05-06 | -$12.30M derived: sum of 2 quarters · filed 2026-02-13 | $35.70M derived: sum of 3 quarters · filed 2026-02-13 | $20.40M derived: sum of 4 quarters · filed 2026-02-13 | |||
| 2023-12-31 | -$56.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | -$8.80M derived: sum of 2 quarters · filed 2026-02-13 | -$24.10M derived: sum of 3 quarters · filed 2026-02-13 | -$50.90M 10-K · filed 2026-02-13 | |||
| 2023-09-30 | $48.00M 10-Q · filed 2024-11-05 | $32.70M derived: sum of 2 quarters · filed 2024-11-05 | $5.90M 10-Q · filed 2024-11-05 | -$126.30M derived: sum of 4 quarters · filed 2025-02-13 | |||
| 2023-06-30 | -$15.30M 10-Q · filed 2024-08-02 | -$42.10M 10-Q · filed 2024-08-02 | -$174.30M derived: sum of 3 quarters · filed 2025-02-13 | -$115.50M derived: sum of 4 quarters · filed 2025-02-13 | |||
| 2023-03-31 | -$26.80M 10-Q · filed 2024-05-07 | -$159.00M derived: sum of 2 quarters · filed 2025-02-13 | -$100.20M derived: sum of 3 quarters · filed 2025-02-13 | -$41.00M derived: sum of 4 quarters · filed 2025-02-13 | |||
| 2022-12-31 | -$132.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | -$73.40M derived: sum of 2 quarters · filed 2025-02-13 | -$14.20M derived: sum of 3 quarters · filed 2025-02-13 | -$4.10M 10-K · filed 2025-02-13 | |||
| 2022-09-30 | $58.80M 10-Q · filed 2023-11-07 | $118.00M derived: sum of 2 quarters · filed 2023-11-07 | $128.10M 10-Q · filed 2023-11-07 | $134.30M derived: sum of 4 quarters · filed 2024-02-15 | |||
| 2022-06-30 | $59.20M 10-Q · filed 2023-08-02 | $69.30M 10-Q · filed 2023-08-02 | $75.50M derived: sum of 3 quarters · filed 2024-02-15 | $110.20M derived: sum of 4 quarters · filed 2024-02-15 | |||
| 2022-03-31 | $10.10M 10-Q · filed 2023-05-02 | $16.30M derived: sum of 2 quarters · filed 2024-02-15 | $51.00M derived: sum of 3 quarters · filed 2024-02-15 | $59.30M derived: sum of 4 quarters · filed 2024-02-15 | |||
| 2021-12-31 | $6.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $40.90M derived: sum of 2 quarters · filed 2024-02-15 | $49.20M derived: sum of 3 quarters · filed 2024-02-15 | $83.20M 10-K · filed 2024-02-15 | |||
| 2021-09-30 | $34.70M 10-Q · filed 2022-10-28 | $34.77M 10-Q · filed 2021-11-03 | $43.00M derived: sum of 2 quarters · filed 2022-10-28 | $77.00M 10-Q · filed 2022-10-28 | $77.01M 10-Q · filed 2021-11-03 | $52.61M derived: sum of 4 quarters · filed 2023-02-10 | |
| 2021-06-30 | $8.30M 10-Q · filed 2022-08-05 | $8.28M 10-Q · filed 2021-07-30 | $42.30M 10-Q · filed 2022-08-05 | $42.24M 10-Q · filed 2021-07-30 | $17.91M derived: sum of 3 quarters · filed 2023-02-10 | -$8.40M derived: sum of 4 quarters · filed 2023-02-10 | |
| 2021-03-31 | $34.00M 10-Q · filed 2022-05-06 | $33.97M 10-Q · filed 2021-04-30 | $9.61M derived: sum of 2 quarters · filed 2023-02-10 | -$16.70M derived: sum of 3 quarters · filed 2023-02-10 | -$36.38M derived: sum of 4 quarters · filed 2023-02-10 | ||
| 2020-12-31 | -$24.39M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | -$50.70M derived: sum of 2 quarters · filed 2023-02-10 | -$70.38M derived: sum of 3 quarters · filed 2023-02-10 | -$51.60M 10-K · filed 2023-02-10 | |||
| 2020-09-30 | -$26.31M 10-Q · filed 2021-11-03 | -$45.99M derived: sum of 2 quarters · filed 2021-11-03 | -$27.21M 10-Q · filed 2021-11-03 | -$48.02M derived: sum of 4 quarters · filed 2022-02-09 | |||
| 2020-06-30 | -$19.68M 10-Q · filed 2021-07-30 | -$898.00K 10-Q · filed 2021-07-30 | -$21.71M derived: sum of 3 quarters · filed 2022-02-09 | -$8.90M derived: sum of 4 quarters · filed 2022-02-09 | |||
| 2020-03-31 | $18.78M 10-Q · filed 2021-04-30 | -$2.03M derived: sum of 2 quarters · filed 2022-02-09 | $10.78M derived: sum of 3 quarters · filed 2022-02-09 | $5.00M derived: sum of 4 quarters · filed 2022-02-09 | |||
| 2019-12-31 | -$20.81M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | -$8.00M derived: sum of 2 quarters · filed 2022-02-09 | -$13.78M derived: sum of 3 quarters · filed 2022-02-09 | -$14.00M 10-K · filed 2022-02-09 | |||
| 2019-09-30 | $12.81M 10-Q · filed 2020-10-30 | $7.04M derived: sum of 2 quarters · filed 2020-10-30 | $6.81M 10-Q · filed 2020-10-30 | ||||
| 2019-06-30 | -$5.78M 10-Q · filed 2020-07-31 | -$6.00M 10-Q · filed 2020-07-31 | |||||
| 2019-03-31 | -$222.00K 10-Q · filed 2020-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |